Take Limited Reports Strong Q1 FY27 Performance Amid Strategic Pivot into Longevity and Anti-Aging Markets
TAKE Limited, a global technology-driven healthcare company, has announced strong unaudited financial results for the first quarter of fiscal year 2026-27 (Q1 FY 2026-27). The company reported consolidated revenue of ₹30.37 Crore and achieved a net profit of ₹1.06 Crore, reversing prior losses.The performance reflects operational stabilization while TAKE Limited strategically enters the burgeoning Longevity, Biohacking, and Preventive Healthcare sectors.
Q1 FY27 Financial Highlights
TAKE Limited demonstrated significant profitability turnaround in the quarter ended June 30, 2026. Consolidated Revenue from Operations reached ₹3,037.33 Lakhs (₹30.37 Crore), while Total Income stood at ₹3,170.11 Lakhs (₹31.70 Crore).The company reported a consolidated profit of ₹106.26 Lakhs after tax, successfully reversing a net loss of ₹91.00 Lakhs in the corresponding quarter of Q1 FY26.
A key operational success was the sharp reduction in finance costs. Finance costs plummeted by 99.62% year-over-year (YoY) to just ₹0.07 Lakhs, down from ₹17.50 Lakhs in Q1 FY26, reflecting improvements in capital structure and debt management.
Earnings Per Share (EPS) also turned positive, with both basic and diluted EPS registering at ₹0.07 per share (Face Value Re. 1/-), up from the negative ₹0.06 per share recorded in Q1 FY26.
Standalone results were equally robust. Standalone Revenue from Operations surged to ₹1,196.90 Lakhs, significantly up from just ₹0.65 Lakhs in Q1 FY26. Net Profit for the standalone segment turned around, reaching ₹96.83 Lakhs compared to a net loss of ₹216.45 Lakhs recorded in Q1 FY26.
| Financial Metric | Q1 FY27 Performance | Comparison to Q1 FY26 |
|---|---|---|
| Consolidated Revenue from Operations | ₹30.37 Crore | Up from Nil |
| Net Profit After Tax (PAT) | ₹1.06 Crore | Reversed loss of ₹91.00 Lakhs |
| Finance Costs | ₹0.07 Lakhs | Down 99.62% from ₹17.50 Lakhs |
| Basic & Diluted EPS | ₹0.07 per share | Up from negative ₹(0.06) per share |
Strategic Entry into Longevity and Biohacking
Building upon its restructured balance sheet and expertise in life sciences, TAKE Limited has announced a strategic entry into the rapidly growing longevity, biohacking, and preventive healthcare market in India.The company's dual business model combines science-backed nutraceuticals and biohacking consumer products with technology-enabled digital tools designed to track and optimize aspects of human health, including sleep, cognition, and biological aging. This focus aims to generate predictable, margin-accretive revenue streams through high repeat-purchase consumer wellness categories.
Parmeshvar Dhangare, Director of TAKE Limited, stated that the Q1 FY27 results reflect successful operational stabilization. He noted: "Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness." He added that by combining clinical domain expertise with predictive digital tools, the company is building a scalable platform addressing proactive health optimization.
Market Opportunity Analysis
The focus on the longevity market aligns with global growth trends. The worldwide longevity market is projected to expand from USD 27.61 Billion in 2025 to USD 67.03 Billion by 2035, reflecting a 9.41% Compound Annual Growth Rate (CAGR).In the Indian context, the preventive healthcare market reached USD 197 Billion in 2025. Anti-aging supplements alone are expected to grow from USD 168.6 Million in 2025 to USD 341.4 Million by 2033, with anti-aging services anticipated to reach USD 1.06 Billion by 2035.
About TAKE Limited:
TAKE Limited (formerly known as TAKE Solutions Limited) is a technology company providing domainintensive solutions for the life sciences and supply chain industries. The company specializes in scalable digital platforms and data-driven solutions, focusing on helping enterprises improve efficiency and compliance through investments in AI, analytics, and digital health technologies.
TAKE Stock Price Movement
Today, Take Solutions Limited shares edged higher after closing, gaining 1.13% to settle at ₹23.25. The equity saw solid trading activity in the session, with 1.33 million shares traded during market hours.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: